Am J Transplant, Volume 19, Suppl 3 Archives - Page 14 of 214 - ATC Abstracts

2019 American Transplant Congress
Impact of the Pediatric End-Stage Liver Disease Growth Failure Threshold on Waitlist Mortality in Children Awaiting Liver Transplant
S. M. Swenson, J. P. Roberts, S. Rhee, E. R. Perito
University of California, San Francisco, San Francisco, CA
*Purpose: To examine the impact on waitlist mortality of Pediatric End-Stage Liver Disease (PELD)’s incorporation of growth failure (GF) as a threshold variable—present or absent…
2019 American Transplant Congress
Development and Validation of a Capillary Blood Mitra-Based Assay for the Quantitative Determination of Advagraf® Concentrations in Transplant Patients
N. Undre¹, I. Dawson², V. Aluvihare³, N. Kamar⁴, F. Saliba⁵, N. Torpey⁶, S. Anaokar⁷, G. Kazeem¹
¹Astellas Pharma Europe Ltd, Chertsey, United Kingdom, ²Covance Laboratories, Harrogate, United Kingdom, ³Kings College Hospital, London, United Kingdom, ⁴CHU Rangueil, Toulouse, France, ⁵Hôpital Paul-Brousse, Villejuif, France, ⁶Addenbrookes Hospital, Cambridge, United Kingdom, ⁷Astellas Pharma Europe Ltd, Surrey, United Kingdom
*Purpose: Therapeutic drug monitoring of tacrolimus (TAC) requires venepuncture blood samples taken by specialists, requiring patients to attend an outpatient clinic; this can be inconvenient…
2019 American Transplant Congress
Costs of Kidney Recoveries Varies Dramatically across Organ Procurement Organizations
J. P. Roberts¹, J. Bragg-Gresham², P. J. Held³
¹Univ of California-San Francisco, San Francisco, CA, ²University of Michigan, Ann Arbor, MI, ³Stanford, Stanford, CA
*Purpose: Report on the wide variation across OPOs in the cost of kidney recovery from deceased donors.*Methods: Cost reports (CMS 216-94 Form) from 52 Independent…
2019 American Transplant Congress
In Vivo/In Situ Behaviour of Allogeneic Spleen versus Bone Marrow Cells in Wild-Type Neonatal Mice: Insights into Robust Transplant Tolerance Induction
R. A. Bascom, K. Tao, L. J. West
Pediatrics, University of Alberta, Edmonton, AB, Canada
*Purpose: Comparing the behaviour of fully allogeneic spleen (SC) vs bone marrow cells (BMC) in non-conditioned neonatal mice is important for maximizing synergistic interactions between…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies
D. H. Ma¹, H. Sasaki¹, J. M. O¹, K. Ahrens¹, D. Becerra¹, C. G. Rickert¹, D. M. Detelich¹, T. Oura¹, W. Somer¹, I. Rosales², R. N. Pierson¹, J. Markmann¹, J. C. Madsen¹, T. Kawai¹
¹Surgery, MGH, Boston, MA, ²Pathology, MGH, Boston, MA
*Purpose: Genetically modified Galactose-α 1,3-galactose knockout transgenic swine expressing human CD55 (GTKO.hCD55) are resistant to hyperacute rejection of xenografts. We compare anti-CD154 and anti-CD40 antibody-based…
2019 American Transplant Congress
Discovery and Validation of an Early Post-Transplant Biomarker Model Predictive of Chronic Kidney Disease in Liver Transplant Recipients
J. Levitsky¹, S. Asrani², G. Klintmalm², T. Schiano², A. Moss³, K. Chavin⁴, C. Miller⁵, L. Zhao⁶, K. Guo⁶, N. Bridges⁷, J. Odim⁷, M. Brown⁷, D. Ikle⁸, B. Armstrong⁸, M. Abecassis⁹
¹Gastroenterology and Hepatology, Northwestern University, Chicago, IL, ²Baylor, Dallas, TX, ³Mayo Arizona, Phoenix, AZ, ⁴Case Western, Cleveland, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Northwestern University, Chicago, IL, ⁷NIAID, Bethesda, MD, ⁸Rho, Chapel Hill, NC, ⁹Comprehensive Transplant Center, Northwestern University, Chicago, IL
*Purpose: A significant proportion of patients develop chronic kidney disease after liver transplantation (LT). We aimed to develop clinical/protein models to predict future GFR deterioration…
2019 American Transplant Congress
Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
M. Z. Molnar, O. Cseprekal, M. Yazawa, M. Talwar, V. Balaraman, V. Mas, D. Maluf, R. Helmick, L. Campos, N. Nezakatgoo, C. Eymard, P. Horton, R. Verma, A. Jenkins, C. R. Handley, H. Snyder, C. Cummings, U. A. Agbim, B. Maliakkal, S. K. Satapathy, S. P. Nair, J. D. Eason
Methodist University Hospital Transplant Institute, Memphis, TN
*Purpose: There are no data on the safety of kidney transplantation from hepatitis C (HCV) NAT positive donors to HCV naïve recipients. We report the…
2019 American Transplant Congress
Enhanced Recovery after Surgery Protocols in Kidney Transplantation: Time to Change Practice?
A. M. Elsabbagh, I. Ghoneim, A. Moiz, D. Mckenney, M. A. Zawaideh
St. Vincent Abdominal Transplant Center, St. Vincent Hospital, Indianapolis, IN
*Purpose: Enhanced recovery after surgery (ERAS) is a multi-modal perioperative care pathway designed to facilitate early recovery after major surgery by maintaining preoperative body composition…
2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
V. H. Ferreira¹, C. J. Guidos², A. Humar¹, D. Kumar¹
¹UHN, Toronto, ON, Canada, ²SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…